News

Princeton, NJ, November 15, 2022 ─ iQure Pharma Inc. (iQure), a US-based biotech company, has confirmed through preclinical screenings that iQ-007, a novel anticonvulsant and analgesic compound, showed no binding to targets in the drug abuse potential panel.


In line with the FDA guidance document, “Assessment of abuse potential of drugs” from January 2017, a full set of 44 potential targets were tested against a high dose of 100 uM of iQ-007 and no relevant binding was observed.


“This is very good news and an important step in the continued development of iQ-007 as a promising therapeutic,” said iQure Chief Operating Officer Henk de Wilde. “With so many drugs in the epilepsy and pain area showing abuse potential, it is comforting to know that iQ-007 shows no potential for abuse and truly is a non-opioid therapeutic.”


About iQure Pharma

iQure Pharma, a global biotech firm headquartered in the US, is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information about supporting iQure’s initiatives, contact iQure CFO Dr. Anna Rzewuska at anna.rzewuska@iqurepharma.com.

3 November 2022 - In a newly published article in Health Tech World, Henk De Wilde, Chief Operating Officer and R&D Director, iQure Pharma Inc., discusses how better understanding of pain is helping researchers to develop novel therapeutics as non-opioid alternatives to manage neuropathic pain. Neuropathic pain is a severe form of chronic pain that's notoriously hard to treat primarily because of its complex pain biology.


iQure Pharma Inc.'s goal is to provide different approaches that can provide better therapeutics for neuropathic pain, to help the millions around the globe whose "excruciating pain is an inescapable reality of life."


Neuropathic pain patients make up an unwilling part of the opioid crisis, as nearly 60 percent of peripheral neuropathy patients end up taking opioids, often chronically.


Mayo Clinic researchers also reported in 2021, that more patients with newly diagnosed diabetic neuropathy were prescribed opioids during the years spanning 2014-2018 than were prescribed guideline-recommended medications.


Read the full text of the article here: http://ow.ly/KsJu50Lr2lk

Updated: Sep 19

iQure Pharma is one of 25 companies invited to join the NYU Stern School of Business Endless Frontier Labs 2022-2023 cohort dedicated to companies developing treatments that address unmet health needs focused on Life Sciences.


Princeton, NJ, September 19, 2022 ─ iQure Pharma Inc. (iQure), a Princeton-based global biotech company focused on developing novel treatments for neuropathic pain, has announced that it has been selected out of over 1100 companies into the high-profile accelerator EFL, run by the renowned Stern School of Business Business at New York University.


“We are excited to announce that iQure has been selected to join the Endless Frontier Labs 2022-2023 cohort!” said Pawel Zolnierczyk, iQure CEO. “We look forward to working alongside EFL mentors, NYU Stern MBA students, and the other great companies selected for the Life Sciences track.”


Endless Frontier Labs (EFL), a program for early-stage science and technology-based start-ups at New York University’s Stern School of Business, is structured to optimize each start-up’s chance of scaling into a successful company through a goals-based mentoring process. EFL mentors are experienced entrepreneurs who have built and exited successful companies, world-renowned scientists and technical experts, and well-known venture capital and angel investors.


About iQure Pharma

A global biotech firm headquartered in Princeton, New Jersey, iQure Pharma is focused on the development of new therapeutics for CNS, including neuropathic pain, epilepsy and other neurodegenerative diseases. iQure researchers, clinicians, and pharmaceutical professionals work closely with academic partners, industry experts, and patient organizations to build medically and socially beneficial therapies. For more information about supporting iQure’s initiatives, contact iQure CFO Dr. Anna Rzewuska at anna.rzewuska@iqurepharma.com.